GlassScriptPhysician profile
Ralph J Ciccone
NPI 1427007905
$10,776.00
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,866 · 2020: $2,214 · 2021: $3,090 · 2022: $2,458 · 2023: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,392.40 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $2,107.78 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $786.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $683.89 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $605.50 | 2019-2021 | |
| Mylan Specialty L.P. | $530.63 | 2019-2022 | |
| Genzyme Corporation | $520.95 | 2019-2022 | |
| Insmed, INC. | $326.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $293.56 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $285.02 | 2019-2022 | |
| Electromed, INC. | $279.07 | 2019-2022 | |
| Philips North America LLC | $247.56 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $214.62 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $202.87 | 2019-2022 | |
| Grifols USA, LLC | $179.68 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $132.29 | 2019-2020 | |
| Optinose US, INC. | $117.30 | 2022 | |
| Harmony Biosciences LLC | $114.14 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.84 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $96.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $88.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $81.12 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $68.78 | 2019 | |
| Shire North American Group INC | $54.86 | 2019 | |
| Amgen INC. | $39.81 | 2022 | |
| Resmed Corp | $30.61 | 2019-2020 | |
| Eisai INC. | $28.64 | 2020-2021 | |
| United Therapeutics Corporation | $27.80 | 2022 | |
| Vapotherm INC | $24.56 | 2019 | |
| Inspire Medical Systems, INC. | $22.76 | 2023 | Inspire |
| Covis Pharma Gmbh | $18.01 | 2022 | |
| Gilead Sciences, INC. | $14.96 | 2021 | |
| Boston Scientific Corporation | $13.50 | 2019 | |
| Baxter Healthcare | $12.70 | 2022 | |
| Pfizer INC. | $12.64 | 2022 | |
| Circassia INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Ciccone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.